Physicians' Academy for Cardiovascular Education

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

10' education - July 12, 2018 - Prof. Colin Baigent - Oxford, United Kingdom

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - Prof. Christoph Wanner - Würzburg, Germany

Dietary lipids in perspective

10' education - July 10, 2018 - Prof. David Marais - Cape Town, South Africa

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe

Early intervention for lifetime CV risk reduction

10' education - May 30, 2018 - Prof. John Deanfield - London, UK

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

How to manage DOAC-related bleeding

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

10' education - July 12, 2018 - Prof. Colin Baigent - Oxford, United Kingdom
Prof Baigent discusses the key areas of uncertainty about SGLT2 inhibitors in patients with CKD and what ongoing trials will contribute.

Prof Baigent discusses the key areas of uncertainty about SGLT2 inhibitors in patients with CKD and what ongoing trials will contribute.

Oral GLP-1 receptor agonist reduces HbA1c and body weight in T2DM patients

News - July 12, 2018

In the PIONEER 1 and 3 phase 3a trials, oral semaglutide reduced HbA1c and body weight in T2DM patients compared to placebo or sitagliptin.

Gut microbiome diversity is inversely associated with arterial stiffness

Literature - July 12, 2018 - Menni C, et al. - Eur Heart J 2018

In a study of middle-aged female twins, the composition of the gut microbiome was strongly correlated with arterial stiffness, independently of traditional risk factors.

Reduced CV risk with intensive blood pressure treatment in T2DM patients on standard glycemic control

Literature - July 11, 2018 - Tsujimoto T and Kajio H. - Hypertension. 2018
In a subanalysis of the ACCORD BP trial, intensive blood pressure treatment in T2DM patients receiving standard glycemic control was significantly associated with a decreased risk of CV events, including HF hospitalization.

In a subanalysis of the ACCORD BP trial, intensive blood pressure treatment in T2DM patients receiving standard glycemic control was significantly associated with a decreased risk of CV events, including HF hospitalization.

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - Prof. Christoph Wanner - Würzburg, Germany
Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Nut consumption inversely associated with risk on AF and HF

Literature - July 10, 2018 - Larsson SC, et al. - Heart 2018
A prospective study showed an inversed association between nut consumption and incidence of atrial fibrillation and heart failure in the Swedish population.

A prospective study showed an inversed association between nut consumption and incidence of atrial fibrillation and heart failure in the Swedish population.

Dietary lipids in perspective

10' education - July 10, 2018 - Prof. David Marais - Cape Town, South Africa
Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in  persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.

Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.

SGLT2 inhibitor improves CV and renal outcomes in diabetic patients with chronic kidney disease

Literature - July 5, 2018 - Neuen BL, et al. - Circulation 2018
In type 2 diabetes patients at high CV risk and chronic kidney disease, the SGLT2 inhibitor canagliflozin consistently improved CV and renal outcomes across different levels of kidney function.

In type 2 diabetes patients at high CV risk and chronic kidney disease, the SGLT2 inhibitor canagliflozin consistently improved CV and renal outcomes across different levels of kidney function.

CVD risk associated with high Lp(a) reduced at low LDL-c in primary prevention setting

Literature - July 5, 2018 - Verbeek R, et al. - Eur Heart J 2018

In two prospective population cohorts, the increased CVD risk in individuals with high Lp(a) levels was reduced when LDL-c levels were <2.5 mmol/L.

Dual GLP-1 and glucagon receptor agonist improves glycemic control and reduces body weight

Literature - July 4, 2018 - Ambery P et al. - Lancet 2018
In a phase 2a study, the dual GLP-1 and glucagon receptor agonist MEDI0382 improved glycemic control and reduced body weight in patients with stable type 2 diabetes who were overweight or obese.

In a phase 2a study, MEDI0382 improved glycemic control and reduced body weight in patients with stable type 2 diabetes who were overweight or obese.

A large reduction in Lp(a) is necessary to achieve a meaningful reduction of CHD risk

Literature - July 3, 2018 - Burgess S, et al. - JAMA Cardiol 2018

Lp(a) concentrations have to be decreased by approximately 100 mg/dL in order to achieve clinically meaningful reductions in the risk of CHD, as shown by Mendelian randomization analysis.

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK
A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.

A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.